Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human open-label study of GSK3745417 with and without dostarlimab in advanced solid tumors
jRCT2031220077Phase 1Suspended
- Sponsor
- GSK
- Start
- Jan 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 1, open-label trial of GSK3745417 and dostarlimab in Nonhematologic neoplasms (2 arms), sponsored by GSK. Primary endpoints: Number of participants achieving dose-limiting toxicity and Number of participants with adverse events and serious adverse events by severity. Started Jan 2023; status: suspended.
02
Drugs
GSK3745417dostarlimab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031220077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220077.